A study on the significance of probiotic treatment for type 2 diabetes patients with periodontal disease

A study on the significance of probiotic treatment for type 2 diabetes patients with periodontal disease - Probiotic treatment for type 2 diabetes patients with periodontal disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032553

Enrollment

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus and periodontal disease

Interventions

Lactomin is administered 4 grams daily for 60 days. lactomin is not administered.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients with HbA1c greater than 7% with periodontal disease combined.

Exclusion criteria

Exclusion criteria: Patients currently receiving periodontal disease treatment. Patients who changed or increased oral hypoglycemic drugs within the past 3 month. Women who are pregnant or breast feeding. Patients who received diagnosis of malignant tumor within the past year. Patients who developed cardiovascular events within the past year.

Design outcomes

Primary

Measure	Time frame
Improvement of Both HbA1c or glycoalbumin and periodontal disease.	—

Secondary

Measure	Time frame
Improvement of TNF-alfa Improvement of malondialdehyde (MDA) Improvement of total antioxidant capacity (TAC)	—

Countries

Japan

Contacts

Public ContactNobuyuki Koriyama

National Hospital Organization Kagoshima Medical Center The Department of Diabetes and Endocrine Medicine

nb-koriyama@kagomc2.hosp.go.jp099-223-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026